Adjuvant Capital GP, L.P.

CIK 00019351001 companyNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001935100

Recent Transactions

31 trades

Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-16$19.65/sh−15,907→ 377,542 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-16$19.65/sh−84,093→ 1,995,958 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-11-14$16.15/sh−1,522→ 2,080,051 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-11-14$16.15/sh−288→ 393,449 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-10-02$16.07/sh−4,770→ 2,081,573 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-10-02$16.07/sh−902→ 393,737 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-29$16.28/sh−15,764→ 394,639 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-29$16.28/sh−83,337→ 2,086,343 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-28$16.11/sh−1,356→ 410,403 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-28$16.11/sh−7,160→ 2,169,680 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-27$16.07/sh−134→ 411,759 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-27$16.07/sh−707→ 2,176,840 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-13$16.00/sh−64→ 411,893 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-13$16.00/sh−336→ 2,177,547 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-07$16.05/sh−537→ 411,957 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-07$16.05/sh−2,841→ 2,177,883 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-06$16.02/sh−598→ 412,494 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-09-06$16.02/sh−3,164→ 2,180,724 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-08-23$16.00/sh−336→ 2,183,888 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2023-08-23$16.00/sh−64→ 413,092 total
Other
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-06-06$15.00/sh+26,511→ 413,156 total
Other
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-06-06$15.00/sh−26,511→ 2,184,224 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+392,433→ 2,044,069 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+1,651,636→ 1,651,636 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series B Convertible Preferred Stock
2022-03-29−392,433→ 0 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29$15.00/sh+166,666→ 2,210,735 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+74,230→ 386,645 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series A Convertible Preferred Stock
2022-03-29−1,651,636→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+312,415→ 312,415 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series B Convertible Preferred Stock
2022-03-29−74,230→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series A Convertible Preferred Stock
2022-03-29−312,415→ 0 total

Companies

AN2 Therapeutics, Inc.
10% Owner
$ANTX

Recent Filings

Address

C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404

NEW YORK, NY, 10017

View on SEC.gov